Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer

ZHONG Zhenhua; FAN Fengfeng; JIANG Wenqiang; LI Zhanwen

doi:10.3971/j.issn.1000-8578.2022.21.1172

Cancer Research on Prevention and Treatment > 2022 > 49(5): 432-437. > DOI: 10.3971/j.issn.1000-8578.2022.21.1172

ZHONG Zhenhua, FAN Fengfeng, JIANG Wenqiang, LI Zhanwen. Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(5): 432-437. DOI: 10.3971/j.issn.1000-8578.2022.21.1172

Citation:

PDF (3165 KB)

Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer

Department of Breast Center, Ningbo Women and Children's Hospital, Ningbo 315000, China

Funding:

Programs Supported by Ningbo Natural Science Foundation 2018A610324

More Information

Received Date: October 17, 2021
Revised Date: January 18, 2022
Available Online: January 12, 2024

Graphical Abstract

Abstract

Abstract

Objective
To assess whether pregnancy affects the survival of pregnancy-associated breast cancer (PABC), compared with non-PABC.
Methods
We retrospectively analyzed the data of PABC patients.PABC cases and non-PABC cases were matched with 1:2 according to T stage, molecular classification, age of onset and year of diagnosis.The Kaplan-Meier method was used to estimate DFS and OS, and Log rank test was used for comparison.Cox regression analysis was used to evaluate the risk factors that affect the prognosis of PABC.
Results
We enrolled 35 patients in the PABC group (pregnancy: 10;postpartum: 25), and 70 patients in the non-PABC group.The median follow-up time was 68.5 and 70.7 months, respectively.The 5-year DFS was 51.6% in the PABC group, and that of the non-PABC group was 72.8%(χ²=4.72, P=0.029);the 5-year OS of the PABC group and the non-PABC group were similar (χ²=1.769, P=0.183).Cox regression analysis showed that pregnancy was an independent risk factor for DFS of PABC patients (P=0.011).
Conclusion
Patients with breast cancer during pregnancy have a higher risk of recurrence.Further research is necessary to diagnose pregnancy-associated breast cancer earlier and adopt measures to improve the curative effect.
- Breast cancer,
- Pregnancy,
- Prognosis

FullText(HTML)

Competing interests: The authors declare that they have no competing interests.

References (31)

References

[1]	Rojas KE, Bilbro N, Manasseh DM, et al. A Review of Pregnancy-Associated Breast Cancer: Diagnosis, Local and Systemic Treatment, and Prognosis[J]. J Womens Health (Larchmt), 2019, 28(6): 778-784. doi: 10.1089/jwh.2018.7264
[2]	Suelmann BBM, van Dooijeweert C, van der Wall E, et al. Pregnancy-associated breast cancer: nationwide Dutch study confirms a discriminatory aggressive histopathologic profile[J]. Breast Cancer Res Treat, 2021, 186(3): 699-704. doi: 10.1007/s10549-021-06130-w
[3]	Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study[J]. Lancet Oncol, 2012, 13(9): 887-896. doi: 10.1016/S1470-2045(12)70261-9
[4]	Azim Jr HA, Santoro L, Russell-Edu W, et al. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies[J]. Cancer Treat Rev, 2012, 38(7): 834-842. doi: 10.1016/j.ctrv.2012.06.004
[5]	Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis[J]. Breast Cancer Res Treat, 2016, 160(2): 347-360. doi: 10.1007/s10549-016-3989-3
[6]	Suleman K, Osmani AH, Al Hashem H, et al. Behavior and Outcomes of Pregnancy Associated Breast Cancer[J]. Asian Pac J Cancer Prev, 2019, 20(1): 135-138. doi: 10.31557/APJCP.2019.20.1.135
[7]	Ali SA, Gupta S, Sehgal R, et al. Survival outcomes in pregnancy associated breast cancer: a retrospective case control study[J]. Breast J, 2012, 18(2): 139-144. doi: 10.1111/j.1524-4741.2011.01201.x
[8]	Johansson ALV, Stensheim H. Epidemiology of Pregnancy-Associated Breast Cancer[J]. Adv Exp Med Biol, 2020, 1252: 75-79.
[9]	Ploquin A, Pistilli B, Tresch E, et al. 5-year overall survival after early breast cancer diagnosed during pregnancy: A retrospective case-control multicentre French study[J]. Eur J Cancer, 2018, 95: 30-37. doi: 10.1016/j.ejca.2018.02.030
[10]	Madaras L, Kovács KA, Szász AM, et al. Clinicopathological features and prognosis of pregnancy associated breast cancer-a matched case control study[J]. Pathol Oncol Res, 2014, 20(3): 581-590. doi: 10.1007/s12253-013-9735-9
[11]	Goldhirsch A, Winer EP, Coates AS, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. doi: 10.1093/annonc/mdt303
[12]	Loibl S, Schmidt A, Gentilini O, et al. Breast Cancer Diagnosed During Pregnancy: Adapting Recent Advances in Breast Cancer Care for Pregnant Patients[J]. JAMA Oncol, 2015, 1(8): 1145-1153. doi: 10.1001/jamaoncol.2015.2413
[13]	Muñoz-Montaño WR, Cabrera-Galeana P, De la Garza-Ramos C, et al. Prognosis of breast cancer diagnosed during pregnancy and early postpartum according to immunohistochemical subtype: A matched case-control study[J]. Breast Cancer Res Treat, 2021, 188(2): 489-500. doi: 10.1007/s10549-021-06225-4
[14]	Momen NC, Ernst A, Arendt LH, et al. Maternal cancer and congenital anomalies in children-a Danish nationwide cohort study[J]. PLoS One, 2017, 12(3): e0173355. doi: 10.1371/journal.pone.0173355
[15]	Parazzini F, Franchi M, Tavani A, et al. Frequency of Pregnancy Related Cancer: A Population Based Linkage Study in Lombardy, Italy[J]. Int J Gynecol Cancer, 2017, 27(3): 613-619. doi: 10.1097/IGC.0000000000000904
[16]	王雪玮, 王昕, 高纪东. 妊娠期乳腺癌的诊断与治疗[J]. 中国医刊, 2017, 52(2): 20-22. doi: 10.3969/j.issn.1008-1070.2017.02.008 [Wang XW, Wang X, Gao JD. Diagnosis and treatment of pregnancy-associated breast cancer[J]. Zhongguo Yi Kan, 2017, 52(2): 20-22. ] doi: 10.3969/j.issn.1008-1070.2017.02.008
[17]	Jin YC, Du JX, Fu SM, et al. A retrospective clinical study of patients with pregnancy-associated breast cancer among multiple centers in China (CSBrS-008)[J]. Chin Med J (Engl), 2021, 134(18): 2186-2195. doi: 10.1097/CM9.0000000000001697
[18]	Kieturakis AJ, Wahab RA, Vijapura C, et al. Current Recommendations for Breast Imaging of the Pregnant and Lactating Patient[J]. AJR Am J Roentgenol, 2021, 216(6): 1462-1475. doi: 10.2214/AJR.20.23905
[19]	Goidescu I, Nemeti G, Caracostea G, et al. The role of imaging techniques in the diagnosis, staging and choice of therapeutic conduct in pregnancy associated breast cancer[J]. Med Ultrason, 2019, 21(3): 336-343. doi: 10.11152/mu-1958
[20]	Martínez MT, Bermejo B, Hernando C, et al. Breast cancer in pregnant patients: A review of the literature[J]. Eur J Obstet Gynecol Reprod Biol, 2018, 230: 222-227. doi: 10.1016/j.ejogrb.2018.04.029
[21]	中华医学会外科学分会乳腺外科学组. 妊娠相关性乳腺癌临床诊治专家共识(2020版)[J]. 中华临床医师杂志(电子版), 2020, 14(5): 321-325. doi: 10.3877/cma.j.issn.1674-0785.2020.05.001 [Breast Surgery Group of Surgery Branch of Chinese Medical Association. Expert consensus on clinical treatment of pregnancy-associated breast cancer (2020 Edition)[J]. Zhonghua Lin Chuang Yi Shi Za Zhi(Dian Zi Ban), 2020, 14(5): 321-325. ] doi: 10.3877/cma.j.issn.1674-0785.2020.05.001
[22]	Johansson ALV, Weibull CE, Fredriksson I, et al. Diagnostic pathways and management in women with pregnancy-associated breast cancer (PABC): no evidence of treatment delays following a first healthcare contact[J]. Breast Cancer Res Treat, 2019, 174(2): 489-503. doi: 10.1007/s10549-018-05083-x
[23]	Blundo C, Giroda M, Fusco N, et al. Early Breast Cancers During Pregnancy Treated With Breast-Conserving Surgery in the First Trimester of Gestation: A Feasibility Study[J]. Front Oncol, 2021, 11: 723693. doi: 10.3389/fonc.2021.723693
[24]	Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer[J]. Ann Surg Oncol, 2014, 21(8): 2506-2511. doi: 10.1245/s10434-014-3718-2
[25]	Pandit-Taskar N, Dauer LT, Montgomery L, et al. Organ and fetal absorbed dose estimates from 99mTc-sulfur colloid lymphoscintigraphy and sentinel node localization in breast cancer patients[J]. J Nucl Med, 2006, 47(7): 1202-1208.
[26]	Bae SY, Kim KS, Kim JS, et al. Neoadjuvant Chemotherapy and Prognosis of Pregnancy-Associated Breast Cancer: A Time-Trends Study of the Korean Breast Cancer Registry Database[J]. J Breast Cancer, 2018, 21(4): 425-432. doi: 10.4048/jbc.2018.21.e58
[27]	Peccatori FA, Azim HA Jr, Orecchia R, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up[J]. Ann Oncol, 2013, 24 Suppl 6: vi160-170.
[28]	Chen Q, Qiu YR, Zhang MD, et al. Clinical practice guidelines for pregnancy-associated breast cancer: Chinese society of breast surgery (CSBrS) practice guidelines 2021[J]. Chin Med J (Engl), 2021, 134(20): 2395-2397. doi: 10.1097/CM9.0000000000001686
[29]	Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy[J]. Obstet Gynecol, 2012, 120(6): 1267-1272. doi: 10.1097/AOG.0b013e31826c32d9
[30]	O'Sullivan CC, Irshad S, Wang Z, et al. Clinico-pathologic features, treatment and outcomes of breast cancer during pregnancy or the post-partum period[J]. Breast Cancer Res Treat, 2020, 180(3): 695-706. doi: 10.1007/s10549-020-05585-7
[31]	Zhang R, Liu X, Huang W, et al. Clinicopathological features and prognosis of patients with pregnancy-associated breast cancer: A matched case control study[J]. Asia Pac J Clin Oncol, 2021, 17(4): 396-402. doi: 10.1111/ajco.13528

[1]	HE Jiawei, CAO Longnyu, TANG Mengyuan, CUI Hongquan. Causal Relationships Between Immune Cells and Risk of Gastric Cancer: A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(2): 172-176. DOI: 10.3971/j.issn.1000-8578.2025.24.0438
[2]	WU Tong, GAO Fei, TENG Fei, ZHANG Qiaoli. Genetic Determinants of Immune Cells and Hepatocellular Carcinoma Risk: A Bioinformatics and Bidirectional Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2025, 52(1): 42-51. DOI: 10.3971/j.issn.1000-8578.2025.24.0562
[3]	YUAN Chendong, SHU Xufeng, WANG Xiaoqiang, JIE Zhigang. Relationship Between High-Density Lipoprotein Cholesterol and Colorectal Cancer—A Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 847-851. DOI: 10.3971/j.issn.1000-8578.2024.24.0153
[4]	GONG Wanli, HOU Yaqi, WANG Yue, LI Yuan, QI Rongxuan, YU Qi, ZHANG Juan. Immune Cell-Mediated Effect of Lipid Profile on Colorectal Cancer: A Two-Step, Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(10): 831-839. DOI: 10.3971/j.issn.1000-8578.2024.24.0284
[5]	LIU Jingting, ZHOU Yawei, KONG Lingguo, WANG Qiandan, SU Tianxiong, PEI Jianying, LI Yan. Causal Association Between Immune Cells and Cervical Cancer: A Two-Sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(9): 772-778. DOI: 10.3971/j.issn.1000-8578.2024.24.0037
[6]	WANG Yuanhang, SONG Zhiyuan, LU Ping, ZHANG Min. Analysis of Association Between Immune Cells and Breast Cancer Based on Two-sample Mendelian Randomization Method[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 348-352. DOI: 10.3971/j.issn.1000-8578.2024.23.1125
[7]	LIU Longjiao, YAO Yufeng. Circulating Inflammatory Proteins in Relation to Risk of Breast Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2024, 51(5): 342-347. DOI: 10.3971/j.issn.1000-8578.2024.23.1344
[8]	WEI Wei, LIU Ming, XU Jianguo, GAO Ya, SHEN Caiyi, TIAN Jinhui. Causal Relationship Between Acromegaly and Colon Cancer: A Two-sample Mendelian Randomization Study[J]. Cancer Research on Prevention and Treatment, 2023, 50(12): 1209-1213. DOI: 10.3971/j.issn.1000-8578.2023.23.0507
[9]	WANG Mengyuan, XU Hengmin, WANG Jingxuan, PAN Kaifeng, LI Wenqing. Mendelian Randomization Analysis of Research on Risk Factors for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2023, 50(5): 470-476. DOI: 10.3971/j.issn.1000-8578.2023.22.1411
[10]	Xin-ying ZHOU, Hu ZHANG, Hai-yan DAI. Mendelian randomization analysis of the correlation between interleukin and the risk of gynecological tumors[J]. Cancer Research on Prevention and Treatment. DOI: 10.3971/j.issn.1000-8578.20240994

Cited By

Cited by

Periodical cited type(13)

1.	吴杨，隋雨桐，李斌鹏，韩路拓，姜家康. 激酶/转录因子信号通路调控肺癌机制及中医药干预的研究进展. 世界中医药. 2025(01): 142-147+154 .
2.	曹家瑞，冯博，马纯政，陈伟霞，喻江凡，曹莎莎，张振予，欧阳文慧. 中医药调控JAK/STAT信号通路干预肺癌的机制研究进展. 中国实验方剂学杂志. 2025(09): 265-276 .
3.	梁帅，尹怡，刘湘花，汪保英，骆文龙，龙云凯，任振杰，王祥麒. 升降理肺消瘤汤对Lewis肺癌小鼠免疫炎性反应和JAK2/STAT3信号通路的影响. 辽宁中医药大学学报. 2024(04): 27-32 .
4.	张彩蝶，靳艳，张德德. 润肺益肾饮对肺癌荷瘤大鼠的抑瘤作用和肿瘤免疫微环境的影响. 天津医药. 2024(04): 362-366 .
5.	孙喜，王召路，贾谨睿，王梦洋，孙润卓，王鹏，史新娥. 虫草素及其在生猪养殖中的应用. 畜牧兽医杂志. 2024(04): 1-7 .
6.	兰春燕，杨小兰，贺雪峰，赵丹，杨海燕. 甘草苷对胃癌荷瘤小鼠免疫功能的调节作用及机制研究. 中国药房. 2024(15): 1862-1867 .
7.	张景淇，郭静，陈娅欣，蒲玥衡，向俊杰. 中药调控肺癌相关信号通路研究进展. 中国实验方剂学杂志. 2024(19): 233-244 .
8.	张孟恩，韩睿，徐超，庞训胜，王世琴. 地顶孢霉培养物在反刍动物生产中的应用研究进展. 中国畜牧杂志. 2024(12): 70-74 .
9.	高铭，丁美灵，雷紫琴，胡靖文，栾飞，曾南. 荆防败毒散及其中成药制剂研究进展. 中药药理与临床. 2023(05): 112-118 .
10.	朱亚兰，吕世文，曾晨欣，徐媛青. 苍术素对非小细胞肺癌细胞上皮间质转化的影响及机制研究. 浙江医学. 2023(10): 1013-1018 .
11.	陈才伟，陈家亮，李华娟，方芳，文方玲. 虫草素调节MAPK/AP-1信号通路对慢性阻塞性肺疾病大鼠肺组织损伤的影响. 临床肺科杂志. 2023(11): 1656-1661 .
12.	李翔子，王西双，范建伟，杨田野，王丽娟，孙颖，姚景春. 荆防合剂通过抑制JAK2-STAT3信号通路调节荨麻疹小鼠脾脏T淋巴细胞亚群的平衡. 中国中药杂志. 2022(20): 5473-5480 .
13.	沈栩岚，黄凌霞. 虫草素的抗癌机理. 蚕桑通报. 2022(02): 33-34 .

Other cited types(4)

Figures(2) / Tables(2)

Get Citation

PDF

XML

Article views (1194) PDF downloads (412) Cited by(17)

Turn off MathJax

Article Contents

Abstract

References

Clinicopathological Characteristics and Prognosis of 35 Cases of Pregnancy-associated Breast Cancer